Figure 1.
The flowchart begins with an efficacy outcome cohort of 97 participants with congenital athymia treated with cultured thymic tissue implantation (CTTI). A box indicates that 21 participants were excluded because they deceased prior to 12 months. This leads to a study cohort of 76 participants. The study cohort is further divided into three subgroups: HLA Subgroup, PHA Subgroup, and Immune Suppression Subgroup. The HLA Subgroup excludes 6 participants due to ambiguous HLA typing and 35 participants due to completed HLA mismatch. It includes 23 participants with a match of 1 of 6 alleles, 11 participants with a match of 2 of 6 alleles, and 1 participant with a match of 3 of 6 alleles. The PHA Subgroup includes 48 participants with a baseline PHA less than 5000 counts per minute (cpm) and 28 participants with a baseline PHA greater than 5000 cpm. The Immune Suppression Subgroup includes 27 participants who did not receive immune suppression and 49 participants who received immune suppression.
Study design flowchart.